BRACHYTHERAPY (RU-106) FOR CHOROIDAL MELANOMA – OUR EXPERIENCE OF 14 YEARS
Abstract
Background. For many years, malignant melanoma of the choroid was treated with prompt enucleation. Recently several eye preserving methods have been developed. The aim of our study was to report on the therapeutic results in patients with primary choroidal melanoma treated with ruthenium-106 brachytherapy.
Methods. A retrospective chart review of 65 patients treated with ruthenium-106 brachytherapy for choroidal melanoma from 1986 to 1997 was performed. The patients were 22 to 78 years old (mean 54.5 years). The height of the tumors was within the range of 1.5 to 7.1 mm (mean 4.7mm). The mean dose to the apex of the tumor was 100 Gy. Mean follow-up period was 90.6 months (range 22 to 169 months). Fundus photography, diagnostic ultrasound and best corrected visual acuity were performed during each examination before and after radiation.
Results. 12 (18.4%) patients died from metastatic spread and 2 from other causes. Complete tumor regression occurred in 12 (18.4%) patients. Tumor regression was partial in 31 (47.7%) patients. Enucleation because of tumor growth was performed in 11 (16.9%) patients and in 2 for other reasons. 19 (30%) eyes retained visual acuity better than 0.5 and 49% of patients had visual acuity better than 0.1.
Conclusions. Ruthenium brachytherapy has proved to be an effective conservative treatment for uveal melanomas thinner than 7mm. The present results correspond well with data in the literature. Visual outcome correlates with tumor location.
Downloads
References
Scotto J, Fraumeni JF Jr., Lee JA. Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst 1976; 56: 489–91.
Char DH, Stone RD, Irvine AR et al. Diagnostic modalities in choroidal melanoma. Am J Ophthalmol 1980; 89: 223–30.
Char DH, Miller T. Accuracy of presumed uveal melanoma diagnosis before alternative therapy. Br J Ophthalmol 1995; 79: 692–6.
Shields JA, Shields CL. Current management of posterior uveal melanoma. Mayo Clin Proc 1993; 68: 1196–200.
Shields JA, Shields CL, De Potter P, Singh AD. Diagnosis and treatment of uveal melanoma. Semin Oncol 1996; 23: 763–7.
Hungerford JL. Management of ocular melanoma. British Medical Bulletin 1995; 51: 694–716.
Albert DM. The ocular melanoma story, LII Edward Jackson memorial lecture: Part II. Am J Ophthalmol 1997; 123: 729–41.
Kertes PJ, Johnson JC, Peyman GA. Internal resection of posterior uveal melanomas. Br J Ophthalmol 1998; 82: 1147–53.
Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT. Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology 1992; 99: 767– 73.
Vrabec TR, Augsburger JJ, Gamel JW, Brady LW, Hernandez C, Woodleigh R. Impact of local tumor relapse on patient survival after cobalt 60 plaque radiotherapy. Ophthalmology 1991; 89: 984–8.
Augsburger JJ, Mullen D, Kleineidam M. Planned combined I 125 plaque irradiation and indirect ophthalmoscope laser therapy for choroidal malignant melanoma. Ophthalmic Surgery 1993; 24: 76–81.
Augsburger JJ, Kleineidam M, Mullen D. Combined iodine-125 and indirect ophthalmoscope laser therapy of choroidal malignant melanomas: comparison with iodine-125 and cobalt-60 plaque radiotherapy alone. Graefe’s Arch Clin Exp Ophthalmol 1993; 231: 500–7.
Bercher L, Zografos L, Egger E, Chamot L, Uffer S, Gaillaud C et al. Le traitement des melanomes exteriorises de la choroide par faisceau de protons acceleres. Klin Mbl Augenheilk 1992; 200: 440–3.
Zografos L, Bercher L, Egger E et al. Le traitement des tumeurs oculaires par faisceau de protons acceleres. Klin Mbl Augenheilk 1992; 200: 431–5.
Saornil MJ, Egan KM, Gragoudas ES, Seddon JM, Walsh SM, Albert DM. Histopathology of proton beam-irradiated vs. enucleated uveal melanomas. Arch Ophthalmol 1992; 110: 1112–8.
Char DH, Castro JR, Kroll SM, Irvine AR, Quivery JM, Stone RD. Five-year follow-up of helium ion therapy for uveal melanoma. Arch Ophthalmol 1990; 108: 209–14.
Char DH, Quivery JM, Castro JR, Kroll SK, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. Ophthalmology 1993; 100: 1547–54.
Char CH, Kroll SM, Castro J. Ten-year follow-up of helium ion therapy for uveal melanoma. Am J Ophthalmol 1998; 25: 81–9.
Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 1996; 80: 102–8.
Damato BE, Paul J, Foulds WS. Risk factors for metastatic uveal melanoma after trans-scleral local resection. Br J Ophthalmol 1996; 80: 109–16.
Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, Bleeker JC. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol 1995; 113: 315–21.
Shields CL, Shields JA, De Potter P, Kheterpal S. Transpupillary thermotherapy in the management of choroidal melanoma. Ophthalmology 1996; 103: 1642–50.
Shields CL, Shields JA, Cater J, Lois N, Edelstein C, Gündüz K et al. Transpupillary thermotherapy for choroidal melanoma. Tumor control and visual results in 100 consecutive cases. Ophthalmology 1998; 105: 581–90.
De Potter P, Shields CL, Shields JA, Cater JR, Tardio DJ. Impact of enucleation versus plaque radiotherapy in the management of juxtapapillary choroidal melanoma on patient survival. Br J Ophthalmol 1994; 78: 109–14.
Augsburger JJ, Correa ZM, Freire J, Brady LW. Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 1998; 105: 1670–8.
Guthoff R, Frischmut J, Jensen OA, Bjerrum K, Prause JU. Das Aderhautmelanom. Eine retrospektive randomisierte Vergleichtsstudie Ruthenium-Bestrahlung vs. Enucleation. Klin Mbl Augenheilk 1992; 200: 257–61.
Lommatzsch PK. Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years experience. Br J Ophthalmol 1986; 70: 844–51.
Char DH. Clinical ocular oncology. 2nd ed. Philadelphia: Lippincott-Raven Publishers 1997, 114–60.
Shields JA, Shields CL. Management of posterior uveal melanoma. In: Shields JA, Shields CL. Intraocular tumors: a text and atlas. Philadelphia: W. B. Saunders Company, 1992: 171–99.
Lommatzsch PK. Radiotherapie der intraokularen Tumoren, insbesondere bei Aderhautmelanom. Klein Mbl Augenheilk 1979; 174: 948–58.
Lommatzsch PK, Werschnik C, Schuster E. Long-term follow-up of Ru-106/ Rh-106 brachytherapy for posterior uveal melanoma. Graefe’s Arch Clin Exp Ophthalmol 2000; 238: 129–37.
Hicks C, Foss AJ, Hungerford JL. Predictive pover of screening tests for metastasis in uveal melanoma. Eye 1998; 12: 945–8.
Manschot WA, Lee WR, Van Strik R. Uveal melanoma: updated considerations on current management modalities. Int Ophthalmol 1995–96; 19: 203–9.
Summanen P, Immonen I, Heikkonen J, Tommila P, Laatikainen L, Tarkkanen A. Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surgery 1993; 24: 82–90.
Shields CL, Shields JA, Cater J, Gündüz K, Miyamoto C, Micaily B et al. Plaque radiotherapy for uveal melanoma: Long-therm visual outcome in 1106 consecutive patients. Arch Ophthalmol 2000; 118: 1219–28.
Char DH. Discussion by Devron H. Char MD. Ophthalmology 1991; 98: 390–0.
Gragoudas ES, Egan KM. Uveal melanoma: a rare malignancy. Ophthalmology 2000; 107: 1441–2.
Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol 1997 42: 215–32.
Egan KM, Ryan LM, Gragoudas ES. Survival implications of enucleation after definitive radiotherapy for choroidal melanoma. Arch Ophthalmol 1998; 116: 366–70.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
